Roth Capital Reaffirms “Buy” Rating for Capricor Therapeutics (NASDAQ:CAPR)
Capricor Therapeutics (NASDAQ:CAPR – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at Roth Capital in a report released on Tuesday,Benzinga reports. They presently have a $31.00 target price on the biotechnology company’s stock. Roth Capital’s target price indicates a potential upside of 159.63% from the stock’s current price. Other equities […]
Capricor Therapeutics (NASDAQ:CAPR – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at Roth Capital in a report released on Tuesday,Benzinga reports. They presently have a $31.00 target price on the biotechnology company’s stock. Roth Capital’s target price indicates a potential upside of 159.63% from the stock’s current price. Other equities […]
